Patents by Inventor Frederic Tremblay

Frederic Tremblay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20260152743
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
    Type: Application
    Filed: December 8, 2025
    Publication date: June 4, 2026
    Inventors: Frederic Tremblay, Lucas D. BonDurant, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20260028631
    Abstract: The present invention relates to RNAi agents, e.g., daRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: June 27, 2025
    Publication date: January 29, 2026
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
    Patent number: 12522822
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 13, 2026
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Frederic Tremblay, Lucas D. BonDurant, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
    Patent number: 12480125
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and to methods of preventing and treating an PNPLA3-associated disorder, e.g., Nonalcoholic Fatty Liver Disease (NAFLD).
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: November 25, 2025
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Frederic Tremblay, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20250333737
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: May 8, 2025
    Publication date: October 30, 2025
    Inventors: Gregory Hinkle, Frederic Tremblay, Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner, Stuart Milstein
  • Ketohexokinase (KHK) iRNA compositions and methods of use thereof
    Patent number: 12404508
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Grant
    Filed: October 16, 2023
    Date of Patent: September 2, 2025
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
    Patent number: 12359201
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B 13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: July 15, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Frederic Tremblay, Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner, Stuart Milstein
  • HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20250188456
    Abstract: RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the HMGB1 gene, useful for inhibiting expression of a HMGB1 gene and preventing and treating an HMGB1-associated disorder, e.g., metabolic disorder or non-alcoholic fatty liver disease, e.g., non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: July 10, 2024
    Publication date: June 12, 2025
    Inventors: Gregory Hinkle, Frederic Tremblay, James D. McIninch
  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240150769
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: October 16, 2023
    Publication date: May 9, 2024
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • Ketohexokinase (KHK) iRNA compositions and methods of use thereof
    Patent number: 11926832
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230416748
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disease in a subject.
    Type: Application
    Filed: September 1, 2022
    Publication date: December 28, 2023
    Inventors: Frederic Tremblay, James D. McIninch
  • KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230323363
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Leila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
  • G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230287432
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the G protein-coupled receptor 146 (GPR146). The invention also relates to methods of using such RNAi agents to inhibit expression of a GPR146 gene and to methods of preventing and treating a GPR146-associated disorders, e.g., hypercholesterolemia and atherosclerosis.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 14, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: KEVIN FITZGERALD, FREDERIC TREMBLAY, JAMES D. MCININCH
  • COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION
    Publication number: 20230190785
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the DNAJC15 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of DNAJC15.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 22, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: FREDERIC TREMBLAY, JAMES D. MCININCH
  • COMPOSITIONS AND METHODS FOR INHIBITING MARC1 GENE EXPRESSION
    Publication number: 20230183707
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the MARC1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MARC1.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 15, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: FREDERIC TREMBLAY, JAMES D. MCININCH
  • PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220348926
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and to methods of preventing and treating an PNPLA3-associated disorder, e.g., Nonalcoholic Fatty Liver Disease (NAFLD).
    Type: Application
    Filed: April 27, 2021
    Publication date: November 3, 2022
    Inventors: Frederic Tremblay, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220042014
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
    Type: Application
    Filed: July 12, 2021
    Publication date: February 10, 2022
    Inventors: Frederic Tremblay, Lucas D. BonDurant, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis
  • 17ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof
    Publication number: 20210380985
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B 13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: March 20, 2019
    Publication date: December 9, 2021
    Inventors: Gregory Hinkle, Frederic Tremblay, Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner, Stuart Milstein
  • 17?-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
    Patent number: 11180757
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: November 23, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Frederic Tremblay, Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner, Stuart Milstein
  • Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
    Patent number: 11162103
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: November 2, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Frederic Tremblay, Lucas D. BonDurant, James D. McIninch, Adam Castoreno, Mark K. Schlegel, Charalambos Kaittanis